Quantum Genomics Société Anonyme

BST:2QG Stock Report

Market Cap: €3.6m

Quantum Genomics Société Anonyme Valuation

Is 2QG undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 2QG when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 2QG's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 2QG's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 2QG?

Key metric: As 2QG barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for 2QG. This is calculated by dividing 2QG's market cap by their current book value.
What is 2QG's PB Ratio?
PB Ratio2.2x
Book€1.62m
Market Cap€3.56m

Price to Book Ratio vs Peers

How does 2QG's PB Ratio compare to its peers?

The above table shows the PB ratio for 2QG vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average4.6x
CNW co.don
1xn/a€6.5m
T5O bioXXmed
13.2xn/a€1.4m
MDG1 Medigene
1.1x-4.1%€22.5m
HPHA Heidelberg Pharma
2.8x-33.0%€102.1m
2QG Quantum Genomics Société Anonyme
2.2x108.5%€3.6m

Price-To-Book vs Peers: 2QG is expensive based on its Price-To-Book Ratio (2.2x) compared to the peer average (2.2x).

Price to Book Ratio vs Industry

How does 2QG's PB Ratio compare vs other companies in the DE Biotechs Industry?

3 CompaniesPrice / BookEstimated GrowthMarket Cap
V9Z Aceragen
0.1xn/aUS$3.12m
V9Z Aceragen
0.1xn/aUS$2.18m
O7P NeuBase Therapeutics
0.1xn/aUS$1.39m
No more companies available in this PB range
2QG 2.2xIndustry Avg. 2.4xNo. of Companies3PB00.61.21.82.43+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: 2QG is good value based on its Price-To-Book Ratio (2.2x) compared to the European Biotechs industry average (2.4x).

Price to Book Ratio vs Fair Ratio

What is 2QG's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

2QG PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio2.2x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate 2QG's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Teva Pharmaceutical Industries

US$18.9b

Develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally.

TEV

US$16.05

7D

4.9%

1Y

79.5%

Pharming Group

€492.8m

A biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally.

PHGN

€0.71

7D

0.4%

1Y

-33.2%

Collegium Pharmaceutical

US$966.2m

A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.

354

US$28.60

7D

2.1%

1Y

21.2%